PURPOSE: The yield of comprehensive genomic profiling in recruiting patients to molecular-based trials designed for small subgroups has not been fully evaluated. We evaluated the likelihood of enrollment in a clinical trial that required the identification of a specific genomic change based on our institute-wide genomic tumor profiling. PATIENTS AND METHODS: Using genomic profiling from archived tissue samples derived from patients with metastatic breast cancer treated between 2011 and 2017, we assessed the impact of systematic genomic characterization on enrollment in an ongoing phase II trial (ClinicalTrials.gov identifier: NCT01670877). Our primary aim was to describe the proportion of patients with a qualifying ERBB2 mutation identified by our institutional genomic panel (OncoMap or OncoPanel) who enrolled in the trial. Secondary objectives included median time from testing result to trial registration, description of the spectrum of ERBB2 mutations, and survival. Associations were calculated using Fisher's exact test. RESULTS: We identified a total of 1,045 patients with metastatic breast cancer without ERBB2 amplification who had available genomic testing results. Of these, 42 patients were found to have ERBB2 mutation and 19 patients (1.8%) were eligible for the trial on the basis of the presence of an activating mutation, 18 of which were identified by OncoPanel testing. Fifty-eight percent of potentially eligible patients were approached, and 33.3% of eligible patients enrolled in the trial guided exclusively by OncoPanel testing. CONCLUSION: More than one half of eligible patients were approached for trial participation and, significantly, one third of those were enrolled in NCT01670877. Our data illustrate the ability to enroll patients in trials of rare subsets in routine clinical practice and highlight the need for these broadly based approaches to effectively support the success of these studies.
PURPOSE: The yield of comprehensive genomic profiling in recruiting patients to molecular-based trials designed for small subgroups has not been fully evaluated. We evaluated the likelihood of enrollment in a clinical trial that required the identification of a specific genomic change based on our institute-wide genomic tumor profiling. PATIENTS AND METHODS: Using genomic profiling from archived tissue samples derived from patients with metastatic breast cancer treated between 2011 and 2017, we assessed the impact of systematic genomic characterization on enrollment in an ongoing phase II trial (ClinicalTrials.gov identifier: NCT01670877). Our primary aim was to describe the proportion of patients with a qualifying ERBB2 mutation identified by our institutional genomic panel (OncoMap or OncoPanel) who enrolled in the trial. Secondary objectives included median time from testing result to trial registration, description of the spectrum of ERBB2 mutations, and survival. Associations were calculated using Fisher's exact test. RESULTS: We identified a total of 1,045 patients with metastatic breast cancer without ERBB2 amplification who had available genomic testing results. Of these, 42 patients were found to have ERBB2 mutation and 19 patients (1.8%) were eligible for the trial on the basis of the presence of an activating mutation, 18 of which were identified by OncoPanel testing. Fifty-eight percent of potentially eligible patients were approached, and 33.3% of eligible patients enrolled in the trial guided exclusively by OncoPanel testing. CONCLUSION: More than one half of eligible patients were approached for trial participation and, significantly, one third of those were enrolled in NCT01670877. Our data illustrate the ability to enroll patients in trials of rare subsets in routine clinical practice and highlight the need for these broadly based approaches to effectively support the success of these studies.
Authors: Lynette M Sholl; Khanh Do; Priyanka Shivdasani; Ethan Cerami; Adrian M Dubuc; Frank C Kuo; Elizabeth P Garcia; Yonghui Jia; Phani Davineni; Ryan P Abo; Trevor J Pugh; Paul van Hummelen; Aaron R Thorner; Matthew Ducar; Alice H Berger; Mizuki Nishino; Katherine A Janeway; Alanna Church; Marian Harris; Lauren L Ritterhouse; Joshua D Campbell; Vanesa Rojas-Rudilla; Azra H Ligon; Shakti Ramkissoon; James M Cleary; Ursula Matulonis; Geoffrey R Oxnard; Richard Chao; Vanessa Tassell; James Christensen; William C Hahn; Philip W Kantoff; David J Kwiatkowski; Bruce E Johnson; Matthew Meyerson; Levi A Garraway; Geoffrey I Shapiro; Barrett J Rollins; Neal I Lindeman; Laura E MacConaill Journal: JCI Insight Date: 2016-11-17
Authors: Funda Meric-Bernstam; Lauren Brusco; Kenna Shaw; Chacha Horombe; Scott Kopetz; Michael A Davies; Mark Routbort; Sarina A Piha-Paul; Filip Janku; Naoto Ueno; David Hong; John De Groot; Vinod Ravi; Yisheng Li; Raja Luthra; Keyur Patel; Russell Broaddus; John Mendelsohn; Gordon B Mills Journal: J Clin Oncol Date: 2015-05-26 Impact factor: 44.544
Authors: Ron Bose; Shyam M Kavuri; Adam C Searleman; Wei Shen; Dong Shen; Daniel C Koboldt; John Monsey; Nicholas Goel; Adam B Aronson; Shunqiang Li; Cynthia X Ma; Li Ding; Elaine R Mardis; Matthew J Ellis Journal: Cancer Discov Date: 2012-12-07 Impact factor: 39.397
Authors: Jennifer J Wheler; Filip Janku; Aung Naing; Yali Li; Bettzy Stephen; Ralph Zinner; Vivek Subbiah; Siqing Fu; Daniel Karp; Gerald S Falchook; Apostolia M Tsimberidou; Sarina Piha-Paul; Roosevelt Anderson; Danxia Ke; Vincent Miller; Roman Yelensky; J Jack Lee; David S Hong; Razelle Kurzrock Journal: Cancer Res Date: 2016-05-18 Impact factor: 12.701
Authors: Cynthia X Ma; Ron Bose; Feng Gao; Rachel A Freedman; Melinda L Telli; Gretchen Kimmick; Eric Winer; Michael Naughton; Matthew P Goetz; Christy Russell; Debu Tripathy; Melody Cobleigh; Andres Forero; Timothy J Pluard; Carey Anders; Polly Ann Niravath; Shana Thomas; Jill Anderson; Caroline Bumb; Kimberly C Banks; Richard B Lanman; Richard Bryce; Alshad S Lalani; John Pfeifer; Daniel F Hayes; Mark Pegram; Kimberly Blackwell; Philippe L Bedard; Hussam Al-Kateb; Matthew J C Ellis Journal: Clin Cancer Res Date: 2017-07-05 Impact factor: 12.531
Authors: Shakti H Ramkissoon; Pratiti Bandopadhayay; Jaeho Hwang; Lori A Ramkissoon; Noah F Greenwald; Steven E Schumacher; Ryan O'Rourke; Nathan Pinches; Patricia Ho; Hayley Malkin; Claire Sinai; Mariella Filbin; Ashley Plant; Wenya Linda Bi; Michael S Chang; Edward Yang; Karen D Wright; Peter E Manley; Matthew Ducar; Sanda Alexandrescu; Hart Lidov; Ivana Delalle; Liliana C Goumnerova; Alanna J Church; Katherine A Janeway; Marian H Harris; Laura E MacConaill; Rebecca D Folkerth; Neal I Lindeman; Charles D Stiles; Mark W Kieran; Azra H Ligon; Sandro Santagata; Adrian M Dubuc; Susan N Chi; Rameen Beroukhim; Keith L Ligon Journal: Neuro Oncol Date: 2017-07-01 Impact factor: 12.300
Authors: Laura E MacConaill; Catarina D Campbell; Sarah M Kehoe; Adam J Bass; Charles Hatton; Lili Niu; Matt Davis; Keluo Yao; Megan Hanna; Chandrani Mondal; Lauren Luongo; Caroline M Emery; Alissa C Baker; Juliet Philips; Deborah J Goff; Michelangelo Fiorentino; Mark A Rubin; Kornelia Polyak; Jennifer Chan; Yuexiang Wang; Jonathan A Fletcher; Sandro Santagata; Gianni Corso; Franco Roviello; Ramesh Shivdasani; Mark W Kieran; Keith L Ligon; Charles D Stiles; William C Hahn; Matthew L Meyerson; Levi A Garraway Journal: PLoS One Date: 2009-11-18 Impact factor: 3.240
Authors: Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: Ana C Garrido-Castro; Liam F Spurr; Melissa E Hughes; Yvonne Y Li; Andrew D Cherniack; Priti Kumari; Maxwell R Lloyd; Brittany Bychkovsky; Romualdo Barroso-Sousa; Simona Di Lascio; Esha Jain; Janet Files; Ayesha Mohammed-Abreu; Max Krevalin; Colin MacKichan; William T Barry; Hao Guo; Daniel Xia; Ethan Cerami; Barrett J Rollins; Laura E MacConaill; Neal I Lindeman; Ian E Krop; Bruce E Johnson; Nikhil Wagle; Eric P Winer; Deborah A Dillon; Nancy U Lin Journal: Clin Cancer Res Date: 2020-12-08 Impact factor: 13.801
Authors: Konstantinos Venetis; Edoardo Crimini; Elham Sajjadi; Chiara Corti; Elena Guerini-Rocco; Giuseppe Viale; Giuseppe Curigliano; Carmen Criscitiello; Nicola Fusco Journal: Front Mol Biosci Date: 2022-03-15